Risks Versus Benefits in Combining Immunotherapies

Video

Combining two checkpoint blockades can be very efficacious in treating metastatic melanoma, but the benefits come with increased risk of adverse events, too.

While combining immune checkpoint inhibitors is often an efficacious way to treat advanced melanoma, it can also cause an increase in adverse events, explained Ryan J. Sullivan, MD, assistant professor of medicine at Harvard Medical School and of hematology/oncology at Massachusetts General Hospital.

For patients with widespread disease who were given a poor prognosis, Sullivan typically prescribes a two-drug regimen, since they need the best chance of response in order to live. However, for most other patients, it is appropriate to give them single-agent immunotherapy treatment, and reassess after 6 to 8 weeks.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Related Content